TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
DURHAM, N.C., Sept. 13, 2016 -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that the company is scheduled to present at the following investor conferences:
2016 Aegis Growth Conference
Date: Wednesday, September 21, 2016
Time: 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time)
Location: Encore at Wynn Las Vegas
Webcast: http://ir.heatbio.com/events-presentations. The webcast will be archived on the company’s website for a period of three months.
OktoberINVESTfest 5th Annual Investors Conference
Date: Wednesday, September 28, 2016
Time: 1:15 p.m. Eastern Time
Location: The New York Academy of Sciences
About Heat Biologics, Inc.
Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer. Heat’s highly specific T cell-stimulating platform technologies, ImPACT and ComPACT, form the basis of its product candidates. These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response. Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC). For more information, please visit www.heatbio.com.
CONTACT: For Investor Inquiries: David Waldman 919-240-7133 [email protected] For Media Inquiries: Deanne Eagle Planet Communications 917-837-5866 [email protected]
